Your donations to The BRAIN Foundation are tax-deductible.
This session presents cutting-edge research into how mouse models are being used to help understand ASD in humans. Animal models can provide insights into effects of gene mutations, and non-behavioral features of ASD, such as the role of the immune system, metabolic system, and gastrointestinal tract including possible contributions by the gut microbiome. Knowledge from these studies may not only help inform human research, but may also prove invaluable in testing therapeutics.
The morning session highlights basic science research including organoid development and immunological research related to testing and treatment in ASD.
The afternoon session focuses on neuro-metabolic studies in ASD, including a focus on anti-folate antibodies and treatments, mitochondrial dysfunction and chemical signaling in the nervous system.
Several research studies link gastrointestinal comorbidities to a variety of debilitating symptoms in individuals with ASD at all ages. Improvements in GI symptoms are linked to improvements in behavior & quality of life. This session highlights the latest work in microbiome studies, therapeutics in FDA trials, updates on a longitudinal GI treatment study, & biopsy studies to characterize inflammatory conditions in individuals with ASD.
Repurposed drugs as ASD therapeutics Dr Rossignol, MD, Dr Jyonouchi, MD, Dr Krigsman, MD, Dr Adams, PhD & Dr Yeh, MD
This session presents researchers and physicians with the latest on treatments and solutions geared towards educating physicians, parents and caregivers. Topics range from CBD studies, mitochondrial dysfunction, GI symptoms, to biophotonic devices.
This session brings together industry and academia with a focus on clinical trials.
The morning session highlights assessments in ASD clinical trials in the time of COVID
Industry experts from startups and large pharma will discuss ongoing clinical trials and therapeutics on the path to FDA approval.
This session highlights novel therapeutics from leaders in academia and industry. Leading companies present products in the pipeline for ASD.
This session brings together academic and industry efforts at establishing biomarkers to help diagnose sub-types of medical comorbidities in autism and to measure response to therapeutics and clinical trials.
The biomarker track presents leaders and innovators involved in discovering biomarkers to help identify and track conditions in people with ASD.
Julian Tillman, PhD Roche
Clinical Validation and Biomarkers- what do they do for diagnostics and treatment tracking with Richard Frye, MD, PhD
The venue, people and events were top-notch. If they do it again, I would highly encourage those interested in learning first-hand about emerging autism research and clinical trials to attend this valuable event.
Synchrony 2019 facilitated collaboration between researchers, clinicians and parent advocates on complex autism related issues that can only be fully answered through multidisciplinary collaboration.